Compare UTHR & EIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UTHR | EIX |
|---|---|---|
| Founded | 1996 | 1886 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Electric Utilities: Central |
| Sector | Health Care | Utilities |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.4B | 23.2B |
| IPO Year | 1999 | N/A |
| Metric | UTHR | EIX |
|---|---|---|
| Price | $474.88 | $60.43 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 12 | 12 |
| Target Price | ★ $498.83 | $64.55 |
| AVG Volume (30 Days) | 471.9K | ★ 3.2M |
| Earning Date | 02-25-2026 | 02-26-2026 |
| Dividend Yield | N/A | ★ 5.85% |
| EPS Growth | 16.08 | ★ 123.49 |
| EPS | ★ 26.38 | 7.64 |
| Revenue | $3,128,400,000.00 | ★ $18,088,000,000.00 |
| Revenue This Year | $13.64 | $7.07 |
| Revenue Next Year | $5.78 | $2.47 |
| P/E Ratio | $18.29 | ★ $7.86 |
| Revenue Growth | ★ 13.50 | 4.43 |
| 52 Week Low | $266.98 | $47.73 |
| 52 Week High | $519.99 | $64.34 |
| Indicator | UTHR | EIX |
|---|---|---|
| Relative Strength Index (RSI) | 40.38 | 55.81 |
| Support Level | $479.59 | $58.21 |
| Resistance Level | $512.74 | $61.31 |
| Average True Range (ATR) | 12.53 | 1.15 |
| MACD | -4.34 | -0.05 |
| Stochastic Oscillator | 2.19 | 76.10 |
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.
Edison International is the parent company of Southern California Edison, an electric utility that distributes electricity to 5 million customers in a 50,000-square-mile area of Southern California, excluding Los Angeles. Edison Energy owns interests in nonutility businesses that deal in energy-related products and services. In 2014, Edison International sold its wholesale power generation subsidiary Edison Mission Energy out of bankruptcy to NRG Energy.